Drug development for neglected diseases: a deficient market and a public-health policy failure

  title={Drug development for neglected diseases: a deficient market and a public-health policy failure},
  author={Patrice Trouiller and Piero L. Olliaro and Els Torreele and James Orbinski and Richard Laing and Nathan P Ford},
  journal={The Lancet},

Tables from this paper

Drug discovery and developments in developing countries: bottlenecks and way forward.
Poor economies and technological capabilities, lack of human resources and good management in these countries are the major constraints to progress in research and development work for new drugs.
Recent initiatives and strategies to developing new drugs for tropical parasitic diseases
The tools, institutions and consortia are now in place and evolving to deliver new pharmaceuticals, however, long-term and consistent investment will be required to identify, develop and clinically validate new chemical entities.
Prodrugs for the Treatment of Neglected Diseases
The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas’ disease (American trypanosomiasis), sleeping sickness, sleeping sickness), malaria, sickle cell disease, tuberculosis, leishmaniasis and schisto-miasis.
New hope for neglected diseases
The dominant paradigm for drug discovery and development in the West will not answer the needs of the developing world and is called upon to develop new and creative approaches, couched in a global responsibility to human health, which can deliver the safe, effective and affordable treatments that the poor of the developed world desperately need.
Editorial: Developing drugs for neglected diseases
  • N. White
  • Medicine
    Tropical medicine & international health : TM & IH
  • 2006
Drug resistance is threatening the control of pneumococcal disease, tuberculosis, malaria, shigellosis, typhoid, and leishmaniasis in the developing world and several not-forprofit organizations have formed to address the dire lack of effective diagnostics, vaccines, and drugs for tropical diseases.
Innovation in neglected tropical disease drug discovery and development
The ongoing endeavor at the global scale will ultimately benefit the patients, the countries they are living and, hopefully, the manufacturers who provide new preventive, diagnostic and therapeutic products.
Orphan drug legislation: lessons for neglected tropical diseases.
The case of ODL may offer some useful insights and perspectives for the fight against neglected tropical diseases and small-sized companies, which have played a successful role in the development of orphan drugs for rare diseases, may also represent a good business strategy for the case of tropical diseases.
Rapid Analysis of Pharmacology for Infectious Diseases
The overall objective of infectious disease informatics is to enable the rapid generation of plausible, novel medical hypotheses of test-able pharmacological experiments, by uncovering undiscovered relationships in the wealth of biomedical literature and databases that were collected for other purposes.
Development of and Access to Products for Neglected Diseases
Product approvals for neglected diseases have increased, though progress has been uneven, with malaria appearing to benefit most in the short run from increased funding, while less success has been booked in other disease categories.


Drug development output from 1975 to 1996: what proportion for tropical diseases?
  • P. Trouiller, P. Olliaro
  • Medicine
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 1998
Access to essential drugs in poor countries: a lost battle?
The problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world are focused on: poor-quality and counterfeit drugs; lack of availability of essential drugs due to fluctuating production or prohibitive cost; need to develop field-based drug research to determine optimum utilization; and potential consequences of recent World Trade Organization agreements on the availability of old and new drugs.
Orphan Drug Development — International Program and Study Design Issues
The incentives established by the United States Orphan Drug Act in 1983 initiated significant changes within the pharmaceutical industry regarding resources expended to develop products to treat
Perspectives on stimulating industrial research and development for neglected infectious diseases.
This paper summarizes recent thinking on stimulating industrial research and development (R&D) for neglected infectious diseases and argues that it is critical to enlarge the value of the market for
Drug treatment of tropical parasitic infections: recent achievements and developments.
The integration of schistosomiasis, onchocerciasis, filariasis and helminth control programmes has been considered as a cost-effective method of delivering treatment and it is likely that future control will be based on this optimisation and integration of existing regimens, rather than the development of new agents.
Tropical medicine
This report highlights the current state of and recent advances made in diagnosis, treatment, and prevention in five tropical infections: African trypanosomiasis, leishmaniasis, lymphatic filariasis, malaria, and schistOSomiasis.
Initial lessons from public-private partnerships in drug and vaccine development.
Three R&D-focused partnerships are explored: the International AIDS Vaccine Initiative; the Medicines for Malaria Venture; and the newly formed Global Alliance for TB Drug Development.
The AIDS research model: implications for other infectious diseases of global health importance.
The biomedical research experience with the AIDS epidemic should serve as an important paradigm in the pursuit of this goal and the implications of the AIDS Research Model for other infectious diseases of global health importance are presented.
The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era*
The decrease in the clinical phase for the 1996 to 1998 NCEs represents the first such decline since the mid-1980s and the percent of products first available in the United States represents a considerable increase over that number for previous years.
Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts
Summary objectives To quantify past outcomes of tropical pharmacology research and development (R & D) and to assess past benefits of the American orphan drug act and potential benefits of the future